Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer’s Disease: A Structured Literature Review

Abstract

Background: Sleep disturbances are frequent in Alzheimer’s disease (AD). This review summarizes the impact of sleep disturbances on AD patients and their caregivers and the effects of currently available sleep therapies. Methods: Published studies (January 1985–March 2020) assessing the burden associated with insomnia/sleep disturbances in the AD population and insomnia treatment effects were identified by searching PubMed, Embase and Cochrane Library and screened against inclusion criteria. Findings: This review included 58 studies which assessed patient and caregiver burden, institutionalization, and insomnia treatments in AD patients with sleep disturbances. Sleep disturbances were associated with worse cognition, functional ability, and behavioral and neuropsychological functioning, including increased depression and anxiety. Health status and quality of life of both patients and caregivers were reduced in the presence of sleep disturbances, with caregiver burden driven largely by disruptive nocturnal behaviors including nighttime awakenings and wanderings. Sleep disturbances were also associated with institutionalization. Although significant associations between sleep problems and clinical outcomes were apparent, there was generally no control for other influencing factors (e.g. cognitive status). With respect to insomnia treatments, bright light, and behavioral therapies as well as drugs such as trazodone, risperidone and suvorexant showed some promise in AD patients, but studies were primarily small and limited data were available, particularly in regard to insomnia treatment effects on associated clinical burden. Interpretation: Sleep disturbances are a significant problem for AD patients and caregivers. They are associated with behavioral and psychological problems and cognitive decline and impose a burden on caregivers, but remain poorly characterized and under-researched. As the global population is aging and AD is on the rise, data from larger, prospective trials are required to fully understand the clinical correlates of sleep disturbances and the impact of insomnia treatments on AD patients and their caregivers.

Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database

“…For example, Kishi et al [15], Nakamura and Nagamine [24], and Ueda [16] have reported the clinical usefulness of suvorexant in insomnia patients with various psychiatric comorbidities, including depressive disorders, bipolar disorders, neurocognitive disorders (dementia), and schizophrenia spectrum disorders. It is well known that sleep disturbances impose a huge burden on patients with neurocognitive disorders such as Alzheimer's disease [25]. Randomized clinical trials have examined the role of suvorexant in patients with Alzheimer's disease and insomnia.…”

Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies

“…As observed in a large populational study, sleep disturbances are strongly linked with faster cognitive decline [ 90 ] and the development of dementia [ 91 ]. Indeed, more than 50% of AD patients are affected by sleeping disorders [ 92 ]. In connection with that, both clinical and experimental findings demonstrate that the extracellular levels of AD-associated proteins are modulated by sleep [ 93 , 94 ].…”

What evidence is there for implicating the brain orexin system in neuropsychiatric symptoms in dementia?

“…PwD frequently present with difficulties in falling asleep (58), fragmented sleep (59), and excessive sleepiness during daytime (60). The sleep-wake disturbance in PwD leads to a progressive deterioration of circadian rhythm (61) and, in advanced stages of dementia, even to a reversal of the day-night sleep pattern (58). Sleep disturbance in PwD has been associated with the presence of other NPS such as anxiety and hyperactivity (62).…”